PlexusDx provides personalized medication management through licensed 503A compounding pharmacies and optional genetic testing to identify your unique response patterns
Following the success of the SELECT trial, Wegovy (semaglutide in doses of 1.7 mg and 2.4 mg) received a similar approval in March 2024 for people with overweight or obesity and cardiovascular disease
Its important to note that these clinical trials had specific eligibility criteria, and results may differ based on your personal health circumstances
Wang L, Yi J, Yin XY, Hou JX, Chen J, Xie B, et al
A standalone B-complex tablet wont reliably correct or prevent the deficiency the protocol is designed to head off
These minerals are essential for nerve function, hydration, and muscle control